{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:29:45Z","timestamp":1784251785161,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cervical cancer, one of the most common cancers affecting females in South Africa, commonly requires a cisplatin-based-treatment regimen, which has been associated with ototoxic side effects. However, cisplatin-associated ototoxicity is largely under-reported in South Africa, despite its impact of hearing loss having serious overt ramifications on the quality of life of these patients. Hence, a prospective cohort study was undertaken to assess the audiological changes in female cervical cancer patients receiving cisplatin therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To present details of the feasibility study and initial results on hearing patterns in cervical cancer patients receiving cisplatin chemotherapy. .<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Fifty cervical cancer patients commencing with cisplatin chemotherapy underwent audiological assessments at a hospital in South Africa at various time intervals. Assessments included case history, otoscopic examination, immittance audiometry, pure tone audiometry (including high-frequency audiometry), speech audiometry, and distortion product otoacoustic emission testing. Data analysis involved the use of descriptive statistics and the Cochran-Armitage trend test for a linear trend in proportions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty participants, aged between 32 and 79\u2009years (Mean: 53\u2009years; SD\u2009=\u200911.00), were recruited. Clinical findings revealed an incidence of 100% ototoxic hearing loss at the one-month post-treatment, i.e., 98%\u00a0 after three cycles of cisplatin and 2%\u00a0 at one-month post-chemotherapy. Sensorineural hearing loss and high-frequency tinnitus were most common. Deterioration in hearing thresholds was more evident in the extended high-frequency range, with the number of \u201cno-responses,\u201d from 11,200\u2009Hz to 20,000\u2009Hz, increasing with each successive audiological evaluation. This study further indicated that recruitment and follow-up of study participants within a limited resource setting are possible. However, cognizance must be given to a multidisciplinary approach and constant engagement with participants through regular contact either telephonically or via a short-message-system.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Exposure to cisplatin treatment contributed to hearing loss in females with cervical cancer, highlighting the need for ototoxicity monitoring during chemotherapy treatments. Furthermore, the results indicate that it is possible to conduct prospective cohort studies, using a multidisciplinary approach in limited-resource environments with appropriate planning and training strategies, as this study was able to achieve its aim successfully.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08567-0","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T12:02:39Z","timestamp":1626436959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5282-6144","authenticated-orcid":false,"given":"Jessica","family":"Paken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-8729","authenticated-orcid":false,"given":"Cyril D.","family":"Govender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8789-8439","authenticated-orcid":false,"given":"Mershen","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5589-8327","authenticated-orcid":false,"given":"Birhanu T.","family":"Ayele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-7270","authenticated-orcid":false,"given":"Vikash","family":"Sewram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"8567_CR1","volume-title":"Cervical cancer prevention and early detection from a south African perspective","year":"2017","unstructured":"Denny L, Kuhn L, editors. Cervical cancer prevention and early detection from a south African perspective. Durban: Health Systems Trust; 2017. http:\/\/www.hst.org.za\/publications\/south-african-health-review-2017"},{"key":"8567_CR2","unstructured":"South African National Cancer Registry. Cancer in South Africa; 2017. https:\/\/www.nicd.ac.za\/wp-content\/uploads\/2020\/12\/NCR_2017_Final_02dec2020.pdf"},{"key":"8567_CR3","doi-asserted-by":"publisher","unstructured":"Burt LM, McCormak M, Lecuru F, Kanyike DM, Bvochora-Nsingo M, Ndlovu N, et al. Cervix Cancer in sub-Saharan Africa: an assessment of cervical Cancer management. JCO Global Oncology. 2021;7:173\u201382. https:\/\/doi.org\/10.1200\/GO.20.00079.","DOI":"10.1200\/GO.20.00079"},{"issue":"1","key":"8567_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/20742835.2018.1441694","volume":"10","author":"M Jemu","year":"2018","unstructured":"Jemu M, van Wijk L, Parker M, Jones G. Tumour and treatment factors influencing the outcome of chemo-radiation in stage IIB cervical cancer: a single institution experience. Southern African Journal of Gynaecological Oncology. 2018;10(1):5\u201310. https:\/\/doi.org\/10.1080\/20742835.2018.1441694.","journal-title":"Southern African Journal of Gynaecological Oncology"},{"issue":"4","key":"8567_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/0019-509X.55551","volume":"46","author":"R Arora","year":"2009","unstructured":"Arora R, Thakur JS, Azad RK, Mohindroo NK, Sharma DR, Seam RK. Cisplatin-based chemotherapy: add high-frequency audiometry in the regimen. Indian J Cancer. 2009;46(4):7. https:\/\/doi.org\/10.4103\/0019-509X.55551.","journal-title":"Indian J Cancer"},{"issue":"8","key":"8567_CR6","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/sj.ki.5002434","volume":"72","author":"L Rybak","year":"2007","unstructured":"Rybak L, Ramkumar V. Ototoxicity. Kidney Int. 2007;72(8):931\u20135. https:\/\/doi.org\/10.1038\/sj.ki.5002434.","journal-title":"Kidney Int"},{"issue":"4","key":"8567_CR7","doi-asserted-by":"publisher","first-page":"262","DOI":"10.4103\/0019-509X.55545","volume":"46","author":"H Malhotra","year":"2009","unstructured":"Malhotra H. Cisplatin ototoxicity. Indian J Cancer. 2009;46(4):262\u20133. https:\/\/doi.org\/10.4103\/0019-509X.55545.","journal-title":"Indian J Cancer"},{"issue":"3","key":"8567_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12070-011-0151-8","volume":"63","author":"M Bisht","year":"2011","unstructured":"Bisht M, Bist SS. Ototoxicity: the hidden menace. Indian J Otolaryngol Head Neck Surg. 2011;63(3):255\u20139. https:\/\/doi.org\/10.1007\/s12070-011-0151-8.","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"issue":"4","key":"8567_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/20786204.2013.10874377","volume":"55","author":"N Schellack","year":"2013","unstructured":"Schellack N, Naude A. An overview of pharmacotherapy-induced ototoxicity : review article. S Afr Fam Pract. 2013;55(4):357\u201365. https:\/\/doi.org\/10.1080\/20786204.2013.10874377.","journal-title":"S Afr Fam Pract"},{"key":"8567_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/01.psy.0000133328.03596.fb","volume":"66","author":"K Tambs","year":"2014","unstructured":"Tambs K. Moderate effects of hearing loss on mental health and subjective well-being. Psychosom Med. 2014;66:776\u201382. https:\/\/doi.org\/10.1097\/01.psy.0000133328.03596.fb.","journal-title":"Psychosom Med"},{"key":"8567_CR11","unstructured":"Tye-Murray N. Foundations of aural rehabilitation: children, adults, and their family members: Cengage learning; 2014."},{"issue":"3","key":"8567_CR12","first-page":"403","volume":"9","author":"Y Olgun","year":"2013","unstructured":"Olgun Y. Cisplatin ototoxicity: where we are? J Int Adv Otol. 2013;9(3):403\u201316 http:\/\/search.ebscohost.com\/login.aspx?direct=true&db=a9h&AN=94058566&site=ehost-live.","journal-title":"J Int Adv Otol"},{"issue":"4","key":"8567_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.7196\/samj.7389","volume":"104","author":"H Whitehorn","year":"2014","unstructured":"Whitehorn H, Sibanda M, Lacerda M, Spracklen T, Ramma L, Dalvie S, Ramesar R. High prevalence of cisplatin-induced ototoxicity in Cape Town,\u00a0South Africa. South Afr Med J. 2014;104(4):288\u201391. https:\/\/doi.org\/10.7196\/samj.7389.","journal-title":"South Afr Med J"},{"key":"8567_CR14","unstructured":"American Speech-Language and Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 1994; https:\/\/inte.asha.org\/policy\/g11994-00003\/."},{"key":"8567_CR15","volume-title":"Pharmacology and ototoxicity for audiologists [internet]","author":"SA Fausti","year":"2007","unstructured":"Fausti SA, Helt WJ, Gordon JS. Audiologic monitoring for ototoxicity and patients management. In: Pharmacology and ototoxicity for audiologists [internet]. United States: Thomson Delmar Learning; 2007. [230-51]."},{"issue":"1","key":"8567_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12905-017-0486-8","volume":"17","author":"J Paken","year":"2017","unstructured":"Paken J, Govender CD, Sewram V. Research protocol: cisplatin-associated ototoxicity amongst patients receiving cancer chemotherapy and the feasibility of an audiological monitoring program. BMC Womens Health. 2017;17(1):129. https:\/\/doi.org\/10.1186\/s12905-017-0486-8.","journal-title":"BMC Womens Health"},{"key":"8567_CR17","unstructured":"National Cancer Institute. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 5.0, 2017. [Available from https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf]"},{"key":"8567_CR18","doi-asserted-by":"crossref","unstructured":"Dalal S, Holmes MD, Laurence C, Bajunirwe F, Guwatudde D, Njelekela M, et al. Feasibility of a large cohort study in sub-Saharan Africa assessed through a four-country study. Glob Health Action. 2015;8 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4444761\/.","DOI":"10.3402\/gha.v8.27422"},{"key":"8567_CR19","doi-asserted-by":"publisher","unstructured":"Koshy E, Car J, Majeed A. Effectiveness of mobile-phone short message service (SMS) reminders for ophthalmology outpatient appointments: observational study. BMC Ophthalmol 2008;8. https:\/\/doi.org\/10.1186\/1471-2415-8-9.","DOI":"10.1186\/1471-2415-8-9"},{"key":"8567_CR20","doi-asserted-by":"crossref","unstructured":"Anh\u00f8j J, M\u00f8ldrup C. Feasibility of collecting diary data from asthma patients through mobile phones and SMS (short message service): response rate analysis and focus group evaluation from a pilot study. J Med Internet Res. 2004;6. https:\/\/pubmed.ncbi.nlm.nih.gov\/15631966\/.","DOI":"10.2196\/jmir.6.4.e42"},{"issue":"2","key":"8567_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4103\/0973-1075.156479","volume":"21","author":"MS Malgonde","year":"2015","unstructured":"Malgonde MS, Nagpure P, Kumar M. Audiometric patterns in ototoxicity after radiotherapy and chemotherapy in patients of head and neck cancers. Indian J Palliat Care. 2015;21(2):164.","journal-title":"Indian J Palliat Care."},{"issue":"2","key":"8567_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/annonc\/mdf058","volume":"13","author":"D Strumberg","year":"2002","unstructured":"Strumberg D, Br\u00fcgge S, Korn M, Koeppen S, Ranft J, Scheiber G, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol. 2002;13(2):229\u201336. https:\/\/doi.org\/10.1093\/annonc\/mdf058.","journal-title":"Ann Oncol"},{"issue":"5","key":"8567_CR23","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/s1808-8694(15)30510-3","volume":"75","author":"C Schultz","year":"2009","unstructured":"Schultz C, Goffi-Gomez MVS, Liberman PHP, Carvalho AL. Report on hearing loss in oncology. Braz J Otorhinolaryngol. 2009;75(5):634\u201341. https:\/\/doi.org\/10.1016\/s1808-8694(15)30510-3.","journal-title":"Braz J Otorhinolaryngol."},{"issue":"1","key":"8567_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3892\/ol.2012.997","volume":"5","author":"A Nitz","year":"2013","unstructured":"Nitz A, Kontopantelis E, Bielack S, Koscielniak E, Klingebiel T, Langer T, et al. Prospective evaluation of cisplatin-and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients. Oncol Lett. 2013;5(1):311\u20135. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3525486\/. https:\/\/doi.org\/10.3892\/ol.2012.997.","journal-title":"Oncol Lett"},{"issue":"3","key":"8567_CR25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00000421-199906000-00020","volume":"22","author":"JL Nagy","year":"1999","unstructured":"Nagy JL, Adelstein DJ, Newman CW, Rybicki LA, Rice TW, Lavertu P. Cisplatin ototoxicity: the importance of baseline audiometry. Am J Clin Oncol. 1999;22(3):305\u20138. https:\/\/doi.org\/10.1097\/00000421-199906000-00020.","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"8567_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1590\/S1808-86942012000300018","volume":"78","author":"DA Malucelli","year":"2012","unstructured":"Malucelli DA, Malucelli FJ, Fonseca VR, Zeigeboim B, Ribas A, de Trotta F, et al. Hearing loss prevalence in patients with diabetes mellitus type 1. Braz J Otorhinolaryngol. 2012;78(3):105\u201315.","journal-title":"Braz J Otorhinolaryngol."},{"issue":"Suppl 3","key":"8567_CR27","doi-asserted-by":"publisher","first-page":"S614","DOI":"10.1007\/s12070-013-0630-1","volume":"65","author":"S Agarwal","year":"2013","unstructured":"Agarwal S, Mishra A, Jagade M, Kasbekar V, Nagle SK. Effects of hypertension on hearing. Indian J Otolaryngol Head Neck Surg. 2013;65(Suppl 3):S614\u2013S8.","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"8567_CR28","doi-asserted-by":"publisher","unstructured":"Luque AE, Orlando MS, Leong UC, Allen PD, Guido JJ, Yang H, et al. Hearing function in patients living with HIV\/AIDS. Ear Hear. 2014;35(6):e282\u2013e90. https:\/\/doi.org\/10.1097\/AUD.0000000000000064.","DOI":"10.1097\/AUD.0000000000000064"},{"issue":"3","key":"8567_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/toxics3030268","volume":"3","author":"A Callejo","year":"2015","unstructured":"Callejo A, Sed\u00f3-Cabez\u00f3n L, Juan ID, Llorens J. Cisplatin-induced ototoxicity: effects, mechanisms and protection strategies. Toxics. 2015;3(3):268\u201393. https:\/\/doi.org\/10.3390\/toxics3030268.","journal-title":"Toxics"},{"issue":"11","key":"8567_CR30","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1002\/ar.22578","volume":"295","author":"J Schacht","year":"2012","unstructured":"Schacht J, Talaska AE, Rybak LP. Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec Adv Integr Anat Evol Biol. 2012;295(11):1837\u201350. https:\/\/doi.org\/10.1002\/ar.22578.","journal-title":"Anat Rec Adv Integr Anat Evol Biol"},{"issue":"1","key":"8567_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1471-2458-11-130","volume":"11","author":"D Hasson","year":"2011","unstructured":"Hasson D, Theorell T, Wall\u00e9n MB, Leineweber C, Canlon B. Stress and prevalence of hearing problems in the Swedish working population. BMC Public Health. 2011;11(1):130. https:\/\/doi.org\/10.1186\/1471-2458-11-130.","journal-title":"BMC Public Health"},{"key":"8567_CR32","doi-asserted-by":"crossref","unstructured":"Bokemeyer C, Berger C, Hartmann J, Kollmannsberger C, Schmoll H, Kuczyk M, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77(8):1355. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2150148\/pdf\/brjcancer00084-0161.pdf.","DOI":"10.1038\/bjc.1998.226"},{"key":"8567_CR33","first-page":"41","volume":"55","author":"LB Melamed","year":"1985","unstructured":"Melamed LB, Selim MA, Facs F, Schuchman D. Cisplatin ototoxicity in gynecologic cancer patients. Cancer Treat Rev. 1985;55:41\u20133.","journal-title":"Cancer Treat Rev"},{"key":"8567_CR34","first-page":"19","volume":"66","author":"RR Reddel","year":"1982","unstructured":"Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, and , Tattersall MHN. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rev 1982;66:19\u201323.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"8567_CR35","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/archotol.1994.01880290051009","volume":"120","author":"BW Blakley","year":"1994","unstructured":"Blakley BW, Gupta AK, Myers SF, Schwan S. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg. 1994;120(5):541\u20136. https:\/\/doi.org\/10.1001\/archotol.1994.01880290051009.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"8567_CR36","doi-asserted-by":"publisher","unstructured":"Reavis KM, McMillan G, Austin D, Gallun F, Fausti SA, Gordon JS, et al. Distortion-product otoacoustic emission test performance for ototoxicity monitoring. Ear Hear. 2011;32(1):61\u201374. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5588870\/. https:\/\/doi.org\/10.1097\/AUD.0b013e3181e8b6a7.","DOI":"10.1097\/AUD.0b013e3181e8b6a7"},{"issue":"10","key":"8567_CR37","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1007\/s00405-014-3283-0","volume":"272","author":"G Kirkim","year":"2015","unstructured":"Kirkim G, Olgun Y, Aktas S, Kiray M, Kolatan E, Altun Z, Er\u00e7etin P, Bagriyanik A, Yilmaz O. Ellidokuz H Is there a gender-related susceptibility for cisplatin ototoxicity? Eur Arch Otorhinolaryngol. 2015;272(10):2755\u201363. https:\/\/doi.org\/10.1007\/s00405-014-3283-0.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"6","key":"8567_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/MPH.0b013e318059c220","volume":"29","author":"PP Coradini","year":"2007","unstructured":"Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29(6):355\u201360. https:\/\/journals.lww.com\/jpho-online\/fulltext\/2007\/06000\/ototoxicity_from_cisplatin_therapy_in_childhood.2.aspx. https:\/\/doi.org\/10.1097\/MPH.0b013e318059c220.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"8567_CR39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3109\/15563657808988252","volume":"13","author":"L Helson","year":"1978","unstructured":"Helson L, Okonkwo E, Anton L, Cvitkovic E. Cis-platinum ototoxicity. Clin Toxicol. 1978;13(4):469\u201378. https:\/\/doi.org\/10.3109\/15563657808988252.","journal-title":"Clin Toxicol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08567-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08567-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08567-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T12:09:32Z","timestamp":1626437372000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08567-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8567"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08567-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been conducted in accordance with the Declaration of Helsinki and has been approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (BE 064\/13) and the study site before data collection commenced. Acknowledging the demographic and language profile of the country, communication with patients was undertaken in either English or isiZulu, based on their preference. All participants gave written informed consent, which were available in both languages. Participants were informed as to the nature, and the purpose of the study, any potential risks that may be involved, participation is voluntary, the nature of their participation, their right to withdraw at any time if they so desired, and that refusal to participate did not affect their clinical care. Furthermore, patients were assured of strict confidentiality and anonymity, as all participants were allocated numbers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"822"}}